Bank of America Has Lowered Expectations for Hims & Hers Health (NYSE:HIMS) Stock Price

Hims & Hers Health (NYSE:HIMS) had its target price cut by equities researchers at Bank of America from $26.00 to $21.00 in a report released on Monday,Benzinga reports. The firm presently has an “underperform” rating on the stock. Bank of America‘s target price would indicate a potential upside of 21.81% from the company’s current price.

Other equities analysts have also recently issued reports about the company. Wall Street Zen cut Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. BTIG Research lowered their target price on Hims & Hers Health from $85.00 to $60.00 and set a “buy” rating on the stock in a report on Monday, February 2nd. Evercore initiated coverage on Hims & Hers Health in a research note on Monday, January 12th. They set an “in-line” rating and a $33.00 price target for the company. KeyCorp initiated coverage on shares of Hims & Hers Health in a research report on Tuesday, October 21st. They set a “sector weight” rating for the company. Finally, Zacks Research downgraded shares of Hims & Hers Health from a “hold” rating to a “strong sell” rating in a report on Monday, January 19th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, nine have issued a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $39.32.

Hims & Hers Health Stock Down 10.8%

HIMS opened at $17.24 on Monday. The stock has a market capitalization of $3.92 billion, a price-to-earnings ratio of 31.93, a PEG ratio of 3.21 and a beta of 2.43. The firm has a 50 day moving average price of $32.22 and a 200-day moving average price of $42.77. Hims & Hers Health has a twelve month low of $16.35 and a twelve month high of $72.98. The company has a quick ratio of 1.64, a current ratio of 1.88 and a debt-to-equity ratio of 1.67.

Hims & Hers Health declared that its Board of Directors has authorized a stock repurchase plan on Monday, November 17th that permits the company to buyback $250.00 million in outstanding shares. This buyback authorization permits the company to reacquire up to 3% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.

Insiders Place Their Bets

In other news, insider Deborah M. Autor sold 7,054 shares of the firm’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $258,952.34. Following the sale, the insider directly owned 6,175 shares in the company, valued at $226,684.25. This trade represents a 53.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Oluyemi Okupe sold 23,187 shares of Hims & Hers Health stock in a transaction on Monday, November 17th. The shares were sold at an average price of $36.81, for a total transaction of $853,513.47. Following the transaction, the chief financial officer owned 70,232 shares in the company, valued at approximately $2,585,239.92. This trade represents a 24.82% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 129,337 shares of company stock valued at $4,651,648. Insiders own 17.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in HIMS. VIRGINIA RETIREMENT SYSTEMS ET Al boosted its stake in Hims & Hers Health by 0.8% in the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 25,600 shares of the company’s stock worth $1,452,000 after purchasing an additional 200 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Hims & Hers Health by 6.1% in the third quarter. GAMMA Investing LLC now owns 4,098 shares of the company’s stock worth $232,000 after buying an additional 236 shares in the last quarter. Concurrent Investment Advisors LLC boosted its position in shares of Hims & Hers Health by 1.8% during the third quarter. Concurrent Investment Advisors LLC now owns 13,984 shares of the company’s stock worth $793,000 after acquiring an additional 252 shares during the last quarter. Smartleaf Asset Management LLC grew its stake in Hims & Hers Health by 44.7% during the third quarter. Smartleaf Asset Management LLC now owns 916 shares of the company’s stock valued at $54,000 after acquiring an additional 283 shares in the last quarter. Finally, Bessemer Group Inc. increased its holdings in Hims & Hers Health by 105.8% in the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock valued at $30,000 after acquiring an additional 312 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers pulled its compounded oral semaglutide offering and said it has held “constructive conversations” with stakeholders — a quick damage‑control move that reduces near‑term regulatory exposure. Hims & Hers is scrapping plan for knockoff Wegovy weight-loss pill. Here’s why
• Positive Sentiment: Some analysts/commentators argue the market is overreacting because GLP‑1 weight‑loss was only a portion of revenue and the company’s broader telehealth platform remains intact. That view supports longer‑term recovery potential if legal/regulatory issues are contained. Hims & Hers Health: Don’t Fall For The Hysteria
• Neutral Sentiment: Some analysts and commentators say the company will survive but warn of a painful reset (“washout”) in the stock while management addresses regulatory/legal fallout. That implies more volatility ahead rather than binary insolvency risk. Hims & Hers Health: The Company Will Survive, But Investors Should Expect A ‘Washout’
• Negative Sentiment: Novo Nordisk filed a U.S. patent lawsuit seeking to block Hims & Hers’ compounded semaglutide products and recover damages — this escalates litigation risk and could lead to injunctions or material liability. Novo Nordisk opens new front with patent suit over Hims’ Wegovy copies
• Negative Sentiment: Multiple major outlets report Novo Nordisk’s broader legal offensive and threats that directly target Hims’ GLP‑1 initiative — raising the probability of costly, precedent‑setting litigation. Novo Nordisk sues Hims & Hers over cheaper copycat versions of Wegovy pill, injections
• Negative Sentiment: The FDA issued a warning letter related to Hims’ activities around compounded GLP‑1 products, which increases regulatory uncertainty and could prompt additional enforcement or restrictions. Hims & Hers’ Woes Compound as FDA Hits Company With Warning Letter
• Negative Sentiment: Analysts have trimmed price targets and ratings (Citigroup, TD Cowen, BofA among others) citing higher legal/regulatory risk and revenue uncertainty — a catalyst for further selling pressure. FDA Uncertainty Pushes Analyst To Lower Hims & Hers Forecast
• Negative Sentiment: Shareholder litigation/fraud investigations have been announced, potentially adding legal costs and management distraction. HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation
• Negative Sentiment: Market reaction: heavy volume, steep declines to multi‑month lows and elevated volatility reflect rapid de‑risking by investors; near‑term sentiment will track legal filings and any FDA follow‑ups. Hims & Hers stock poised for heavy losses after quick U-turn on plan for oral Wegovy competitor

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.